SECENDS - PFE

2025

Q4 4 filings

Nov 21

Completed Public Offering of Notes Worth $3.75B

$500M aggregate principal amount of Floating Rate Notes due 2027, $1B aggregate principal amount of 2027 Notes, and so on...

8-K View →

Nov 13

Acquired Metsera for $7.0B

$65.60 per share in cash, plus contingent value rights of up to $20.65 per share

8-K View →

Nov 4

Q3 2025 Earnings Released

Revenue and EPS announced for Q3 2025

8-K View →

Nov 4

Q3 2025 Results

Unable to extract revenue and EPS - financial data not readable in provided XBRL format

10-Q View →

Q3 2 filings

Aug 5

Q2 2025 Results

Revenue and EPS data not available in provided content

10-Q View →

Aug 5

Q2 2025 Earnings

Q2 2025 financial results announced

8-K View →

Q2 4 filings

May 19

Euro Debt Offering

€3.3B notes issued: 2.875%-4.25% rates, 2029-2045 maturities

8-K View →

May 5

Q1 2025 Results

Financial data not accessible in provided format

10-Q View →

Apr 29

Q1 Earnings & $1.2B Cost Savings Program

$1.2B additional savings by 2027, $1.6B implementation costs

8-K View →

Apr 28

Annual Shareholder Meeting

13 directors elected, auditor ratified, exec comp approved, 2 shareholder proposals rejected

8-K View →

Q1 3 filings

Mar 13

2025 Proxy Statement

CEO comp: Not disclosed, Say-on-pay: TBD

DEF 14A View →

Feb 27

FY 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

📌 Completed acquisition of Seagen in December 2023, with full-year 2024 integration and operations including oncology portfolio expansion

10-K View →

Feb 4

Q4 2024 Earnings

Q4 and full-year 2024 financial results announced

8-K View →

2024

Q4 4 filings

Dec 17

2025 Guidance Issued

Full-year 2025 guidance provided, 2024 guidance reaffirmed

8-K View →

Nov 4

Q3 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL data

10-Q View →

Oct 29

Q3 2024 Earnings

Q3 2024 financial results announced

8-K View →

Oct 15

Board Director Election

Mortimer J. Buckley elected to Board

8-K View →

Q3 5 filings

Aug 5

Q2 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q View →

Jul 30

Q2 2024 Earnings

Q2 2024 financial results announced

8-K View →

Jul 26

Executive Compensation Plan Modifications

9,000 employees including 6 named executives get 2-year extensions on TSRUs and PSAs

8-K View →

Jul 10

CSO Departure Announced

Dr. Mikael Dolsten stepping down after 15+ years, successor search initiated

8-K View →

Jul 1

Board Election

Cyrus Taraporevala elected to Board

8-K View →

Q2 4 filings

May 22

Cost Reduction Program Launch

$1.5B savings by 2027, $1.7B one-time costs

8-K View →

May 8

Q1 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL tags

10-Q View →

May 1

Q1 2024 Earnings

Q1 2024 financial results announced

8-K View →

Apr 29

Annual Shareholder Meeting

All 12 directors elected, auditor ratified, executive comp approved

8-K View →

Q1 4 filings

Mar 14

2024 Proxy Statement

CEO comp: Not disclosed, Say-on-pay: TBD

DEF 14A View →

Feb 22

FY2023 2023 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

📌 Completed acquisition of Seagen on December 14, 2023, adding significant oncology capabilities to Pfizer's pipeline

10-K View →

Jan 30

Q4 2023 Earnings

Q4 and full-year 2023 financial results announced

8-K View →

Jan 10

Mini-Tender Offer Received

TRC Capital offers $27.35/share for 4M shares, 4.4% below market

8-K View →